- Home
- APVO vs PTIX Comparison
APVO vs PTIX Comparison
Compare APVO & PTIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APVO
- PTIX
- Stock Information
- Founded
- APVO 2016
- PTIX 1994
- Country
- APVO United States
- PTIX United States
- Employees
- APVO N/A
- PTIX N/A
- Industry
- APVO Biotechnology: Pharmaceutical Preparations
- PTIX Biotechnology: Pharmaceutical Preparations
- Sector
- APVO Health Care
- PTIX Health Care
- Exchange
- APVO Nasdaq
- PTIX Nasdaq
- Market Cap
- APVO 4.1M
- PTIX 3.3M
- IPO Year
- APVO N/A
- PTIX 2016
- Fundamental
- Price
- APVO $3.23
- PTIX $3.65
- Analyst Decision
- APVO Strong Buy
- PTIX
- Analyst Count
- APVO 1
- PTIX 0
- Target Price
- APVO $5,920.00
- PTIX N/A
- AVG Volume (30 Days)
- APVO 6.7M
- PTIX 183.9K
- Earning Date
- APVO 08-07-2025
- PTIX 08-13-2025
- Dividend Yield
- APVO N/A
- PTIX N/A
- EPS Growth
- APVO N/A
- PTIX N/A
- EPS
- APVO N/A
- PTIX N/A
- Revenue
- APVO N/A
- PTIX N/A
- Revenue This Year
- APVO N/A
- PTIX N/A
- Revenue Next Year
- APVO N/A
- PTIX N/A
- P/E Ratio
- APVO N/A
- PTIX N/A
- Revenue Growth
- APVO N/A
- PTIX N/A
- 52 Week Low
- APVO $2.81
- PTIX $2.35
- 52 Week High
- APVO $485.37
- PTIX $15.54
- Technical
- Relative Strength Index (RSI)
- APVO 34.28
- PTIX 53.21
- Support Level
- APVO $2.81
- PTIX $3.55
- Resistance Level
- APVO $13.11
- PTIX $3.97
- Average True Range (ATR)
- APVO 1.10
- PTIX 0.23
- MACD
- APVO 0.30
- PTIX 0.04
- Stochastic Oscillator
- APVO 4.08
- PTIX 81.83
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
About PTIX Protagenic Therapeutics Inc.
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's main compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.